All In Biotech

Drug Trial Radar · NCT00168792

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 1,671 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,671

Actual

Start

Nov 2003

Primary completion

Jul 2006

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Genentech, Inc.
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

Conditions

  • Myocardial Infarction

Interventions

  • TenecteplaseDrug

  • PCIProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death or cardiogenic shock or congestive heart failure within 90 daysTime frame: 90 days

Locations

176 sites in 18 countries. Site status is shown where the registry gives one.

  • Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • Boehringer Ingelheim Investigational Site

    Fort Lauderdale, Florida

  • Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • Boehringer Ingelheim Investigational Site

    Macan, Georgia

  • Boehringer Ingelheim Investigational Site

    Detroit, Michigan

  • Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • Boehringer Ingelheim Investigational Site

    Providence, Rhode Island

  • Boehringer Ingelheim Investigational Site

    Feldkirch, Austria

  • Boehringer Ingelheim Investigational Site

    Sankt Pölten, Austria

  • Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • Boehringer Ingelheim Investigational Site

    Wiener Neustadt, Austria

  • Boehringer Ingelheim Investigational Site

    Aalst, Belgium

  • Boehringer Ingelheim Investigational Site

    Anderlecht, Belgium

  • Boehringer Ingelheim Investigational Site

    Angleur, Belgium

  • Boehringer Ingelheim Investigational Site

    Antwerp, Belgium

  • Boehringer Ingelheim Investigational Site

    Bonheiden, Belgium

  • Boehringer Ingelheim Investigational Site

    Bouge, Belgium

  • Boehringer Ingelheim Investigational Site

    Bruges, Belgium

  • Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • Boehringer Ingelheim Investigational Site

    Charleroi, Belgium

  • Boehringer Ingelheim Investigational Site

    Genk, Belgium

  • Boehringer Ingelheim Investigational Site

    Ghent, Belgium

  • Boehringer Ingelheim Investigational Site

    Gilly, Belgium

  • Boehringer Ingelheim Investigational Site

    Huy, Belgium

  • Boehringer Ingelheim Investigational Site

    La Louvière, Belgium

  • Boehringer Ingelheim Investigational Site

    Leuven, Belgium

  • Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • Boehringer Ingelheim Investigational Site

    Namur, Belgium

  • Boehringer Ingelheim Investigational Site

    Roeselare, Belgium

  • Boehringer Ingelheim Investigational Site

    Blumenau - SC, Brazil

  • Boehringer Ingelheim Investigational Site

    Curitiba - PR, Brazil

  • Boehringer Ingelheim Investigational Site

    Marília - SP, Brazil

  • Boehringer Ingelheim Investigational Site

    Passo Fundo - RS, Brazil

  • Boehringer Ingelheim Investigational Site

    Porto Alegre - RS, Brazil

  • Boehringer Ingelheim Investigational Site

    São Paulo - SP, Brazil

  • Boehringer Ingelheim Investigational Site

    Victoria, British Columbia, Canada

  • Boehringer Ingelheim Investigational Site

    Greater Sudbury, Ontario, Canada

  • Boehringer Ingelheim Investigational Site

    Saint-Foy, Ontario, Canada

  • Boehringer Ingelheim Investigational Site

    Montreal, Quebec, Canada

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.